For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Prudential Financial, Inc. (PRU) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-25): Designation Low · Gem Score -25 (−100…+100 Quality+Value blend) · Quality 23 · Value -64 · Sentiment -46 (timing only, not weighted) · Composite fair value $77.37 vs $119.96 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Prudential Financial, Inc.
PRU NYSEPrudential Financial, Inc. is a diversified financial services company specializing in insurance, retirement, and investment management solutions for individuals, institutions, and corporate clients. The company provides a broad range of products, including life insurance, annuities, group insurance benefits, and retirement-related services that support income protection and long-term financial planning. Through its global investment management business, PGIM, Prudential Financial offers asset management strategies across public and private markets to pension funds, governments, corporations, and retail investors. The United States and Japan represent its largest markets, complemented by operations in select emerging economies. Today, Prudential Financial plays a significant role in the life insurance and retirement ecosystem, helping manage risk, provide income security, and allocate capital across global financial markets. Headquartered in Newark, New Jersey, and founded in the United States, it operates as a major participant in the financial services and insurance industries.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 9.99
Total Equity: $32.44B
Shares: 357,957,958
Total Debt: $22.96B
Cash: $19.71B
EBITDA: N/A
Total Debt: $22.96B
Cash: $19.71B
Revenue: $60.97B
Revenue: $60.97B
Revenue: $60.97B
Total Equity: $32.44B
Tax Rate: 22.6%
Equity: $32.44B
Total Debt: $22.96B
Cash: $19.71B
Current Liabilities: N/A
Long-Term Debt: $21.26B
Total Debt: $22.96B
Total Equity: $32.44B
Shares: 357,957,958
Shares: 357,957,958
CapEx: $0.00
Shares: 357,957,958
Stock Price: $119.96
Net Income: $3.58B
Industry Benchmarks
Income Statement (Annual)
Last updated: Jul 27, 2026 12:34am (29d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $71.1B | $57.0B | $54.3B | $70.7B | $61.0B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $13.5B | $12.7B | $13.2B | $13.6B | $13.2B |
| Operating Income | — | — | — | — | — |
| Net Income | $8.9B | -$1.6B | $2.5B | $2.7B | $3.6B |
| EBITDA | — | — | — | — | — |
| EPS | $19.95 | $-4.49 | $6.76 | $7.54 | $10.05 |
| EPS (Diluted) | $19.51 | $-4.49 | $6.74 | $7.50 | $9.99 |
Balance Sheet (Annual)
Last updated: Jul 27, 2026 12:06am (29d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $12.9B | $17.3B | $19.4B | $18.5B | $19.7B |
| Total Current Assets | — | — | — | — | — |
| Total Assets | — | — | — | $735.6B | $773.7B |
| Current Liabilities | — | — | — | — | — |
| Long-Term Debt | $18.6B | $20.0B | $20.0B | $20.4B | $21.3B |
| Total Liabilities | — | — | — | $705.5B | $738.2B |
| Total Equity | $61.9B | $30.6B | $27.8B | $27.9B | $32.4B |
| Retained Earnings | $36.7B | $31.7B | $32.4B | $33.2B | $34.8B |
Cash Flow (Annual)
Last updated: Jul 27, 2026 12:34am (29d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $9.8B | $5.2B | $6.5B | $8.5B | $6.3B |
| Capital Expenditure | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | -$1.8B | -$1.8B | -$1.8B | -$1.9B | -$1.9B |
| Stock Buybacks | -$2.5B | -$1.5B | -$1.0B | -$1.0B | -$1.0B |
| Net Change in Cash | -$921.0M | $4.4B | $2.2B | -$943.0M | $1.2B |
Growth Trends (YoY %)
Last updated: Jul 27, 2026 12:34am (29d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -19.9% | -4.7% | +30.2% | -13.7% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | — | — | — | — |
| Net Income Growth | -118.6% | +251.1% | +9.6% | +31.1% |
| EBITDA Growth | — | — | — | — |
Dividend History (Last 20)
Last updated: Jul 25, 2026 3:24am (31d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-26 | $1.40 | — | — | — |
| 2026-02-17 | $1.40 | — | — | — |
| 2025-11-18 | $1.35 | — | — | — |
| 2025-08-19 | $1.35 | — | — | — |
| 2025-05-20 | $1.35 | — | — | — |
| 2025-02-18 | $1.35 | — | — | — |
| 2024-11-19 | $1.30 | — | — | — |
| 2024-08-20 | $1.30 | — | — | — |
| 2024-05-20 | $1.30 | — | — | — |
| 2024-02-16 | $1.30 | — | — | — |
| 2023-11-20 | $1.25 | — | — | — |
| 2023-08-21 | $1.25 | — | — | — |
| 2023-05-22 | $1.25 | — | — | — |
| 2023-02-17 | $1.25 | — | — | — |
| 2022-11-21 | $1.20 | — | — | — |
| 2022-08-22 | $1.20 | — | — | — |
| 2022-05-23 | $1.20 | — | — | — |
| 2022-02-14 | $1.20 | — | — | — |
| 2021-11-22 | $1.15 | — | — | — |
| 2021-08-23 | $1.15 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-23 02:44Recovery pays +163%; another quarter like the worst recent one costs 29%. Ratio 5.6:1. Caveat: revenue-DCF fits financials poorly (reported revenue omits net interest) — treat the legs as rough.
| Case | Growth | Margin | Fair value | vs price ($119.96) |
|---|---|---|---|---|
| Bull — recovery | +17% | 10.3% | $315.47 | +163% |
| Base — stabilizes | +11% | 9.0% | $232.43 | +94% |
| Bear — keeps slipping | +6% | 7.6% | $167.20 | +39% |
| Stress — last quarter repeats | -8% | 6.0% | $84.95 | -29% |
Narrative Economics
market-narrative step).
Claude Reading
The raw numbers on PRU are messier than any single model admits, and I want to start there before adjudicating. Reported revenue swings from $8.35B (Q3 2023) to $23.51B (Q1 2024) to $13.47B (Q1 2025) — this isn't a business in "decline," it's an insurance accounting artifact driven by reinsurance transactions, pension risk transfer deal timing, and mark-to-market on the investment portfolio. Annual revenue went $71.15B → $56.96B → $54.27B → $70.68B → $60.97B; the "-13.7% YoY" recent revenue figure is arithmetic noise, not signal. What actually matters for a life insurer is book value, spread income, PGIM fee flow, and capital return — and on those, NI recovered from -$1.65B (2022) to $2.49B → $2.73B → $3.58B, a genuine trajectory. ROE of 11%, P/B of 1.32, P/E of 12, 4.6% yield with 54% payout — these are the numbers of a normalized, moderately profitable insurer, not a fallen angel and not a bargain.
The synthesis verdict of $69.77 fair value against a $119.96 price (-42%) is where I dissent most strongly. A DCF on a life insurer with volatile GAAP revenue is close to useless — you cannot discount cash flows you can't identify (FCF is literally blank in the data file), and running P/S or EV/Sales multiples against a top line that includes premiums, investment gains, and reinsurance flows is a category error. The peer group (MET, AFL, LNC) trades at 9-12x earnings and 1.0-1.5x book; PRU at 12x and 1.32x book is squarely in-line, not 72% overvalued. The "$70 fair value" implies PRU should trade at ~0.77x book and ~7.7x earnings, which would be a distressed multiple this business hasn't warranted since the GFC. I think the synthesis model is anchoring on broken revenue-based methods and the Market Narrative layer is amplifying that error by treating a mechanical DCF miss as evidence of narrative premium.
The Market Forces contrarian read (31% earnings growth, insider buying, compressed valuation) is directionally right but I'd caution against it too. Those three "P-Purchase" insider entries dated 2026-07-15 for 3M shares each are almost certainly duplicated data errors or a mislabeled 10b5-1 grant — 9M shares at $120 is over $1B, which would be one of the largest insider buys in financials history and would be front-page news. I'd throw that signal out entirely until verified. Strip that out and you have a mature insurer with decent earnings recovery, a real 4.6% yield, a covered payout, and $19.7B cash against $23B debt — solid but not exciting. The Pre-Flight framing as "dividend-income" is the correct lens; the "fallen-angel" narrative archetype is overwrought given the stock is near highs.
A careful contrarian argument against my own moderate stance: life insurance is genuinely in secular headwind (declining household formation, term over whole-life shift, PGIM AUM sensitivity to equity drawdowns), the operating CF of $6.27B against a $41.67B market cap is only a 15% CF yield which isn't cheap for a no-growth financial, and rate normalization from here compresses the spread tailwind PRU enjoyed in 2023-24. That's the real bear case — not "72% overvalued," but "fairly valued with limited upside and cyclical downside." My verdict: the synthesis is wrong on magnitude, Market Forces is right on direction but leaning on a bogus insider signal, and the honest read is PRU is a fine income holding at $110-125 with fair value probably $105-115 on normalized 10x earnings + book. Not a buy at $120, not a short, and definitely not a $70 stock.
GPT Reading
What jumps out to me in the raw data is not cheapness but normalization after a very volatile period. Annual net income has climbed from a 2022 loss of $1.65B to $2.49B in 2023, $2.73B in 2024, and $3.58B in 2025, while ROE sits at 11.0% on $32.44B of equity. That is respectable, but not exceptional enough to demand a premium multiple. The balance sheet is fine rather than fortress-like: $22.96B of debt against $19.71B of cash leaves modest net debt, and the debt-to-equity ratio of 0.71 is comfortable for a large insurer but not a hidden source of upside. The key valuation fact is simple: at $41.67B market cap, investors are paying 1.32x book and 12.0x earnings for a company with a 5.9% net margin and no visible top-line growth trend you can underwrite with confidence. That can work for a stable compounder; PRU’s reported numbers instead describe a cyclical, accounting-noisy income vehicle.
The quarterly pattern reinforces that view. Revenue has ranged from $8.35B to $23.51B in the last seven disclosed quarters, and margins have swung from -9.6% to +8.7%; even the more recent sequence shows $1.20B of net income in Q2 2024, $448M in Q3 2024, a slight loss of $57M in Q4 2024, then $707M in Q1 2025. I agree with Opus that this volatility makes revenue-based valuation methods suspect, but I do not read the earnings recovery as strong enough to dismiss downside risk. If 2025’s $3.58B is the current normalized earnings power, the stock is already at about 11.6x that figure. For a mature life insurer with a 4.6% dividend yield and payout ratio of 53.9%, that is reasonable to full, not mispriced on the low side. The market is paying today for stability that the reported income stream has not fully demonstrated.
Opus argues the "$70 fair value" is methodologically broken because DCF, P/S, and EV/revenue are poor tools for a life insurer. I agree with that criticism decisively. On this dataset, a sales-based bear case is junk analysis: annual revenue has been $71.15B, then $56.96B, then $54.27B, then $70.68B, then $60.97B, while earnings moved independently from +$8.87B to -$1.65B to +$3.58B. That tells you the top line is not an economic anchor. I also agree with Opus that the three identical 3,000,000-share insider purchases should be discarded as likely bad data. Where I disagree is on their comfort with a $105-115 fair value band. Using the actual book value in the file, 1.15x book would imply roughly $105-106 of equity value, but their simultaneous use of 10x normalized earnings only supports $100-110 if normalized earnings are truly around $3.6B to $4.0B. At $119.96, the market is already above both anchors. So Opus is right that this is not a 42% short; they are too generous in calling it merely a hold range up to $125.
I also disagree with Opus’s softer framing that PRU is “not a bargain” but essentially fine as an income holding at current levels. The issue is not existential decline; it is that investors are paying a mild premium for middling returns. An 11% ROE business trading at 1.32x book is not obviously wrong, but it leaves little room if rates move against spreads, if PGIM fee income softens with markets, or if another quarter like Q4 2024 appears. The Delvantic AI Findings correctly rejects the “fallen angel” story and the broken synthesis DCF, but it understates the re-rating risk embedded in paying 12x earnings for a no-growth insurer whose annual revenue in 2025 was still below 2021 by more than $10B. I would not short it aggressively because the dividend and capital base matter, but I would not characterize $120 as comfortably fair either.
A careful skeptic of both my view and Opus’s would say we are both over-reading noisy GAAP outputs and underweighting what matters for life insurers: reserve adequacy, spread income durability, capital return capacity, and segment-level earnings quality, none of which are provided here. That skeptic would also note that $6.27B of operating cash flow versus a $41.67B market cap is not obviously expensive, and that if book value compounds while the 4.6% yield is sustained, a 12x multiple can be justified. Fair. But on the data actually in hand, the burden of proof is on the bull at $120, not on the bear.
Grok Reading
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.
Advanced Analysis Forensic deep-dive · separate lenses
Prudential is a scale life-and-annuity franchise generating consistent free cash flow (6.27B in the latest year, averaging roughly 7B across five years) with OCF/NI of 1.09x and slightly negative accruals (-0.6% of assets), suggesting reported earnings are backed by cash. Diluted share count has fallen from 454.5M to 358.0M, a -5.8% CAGR, meaningfully concentrating per-share economics. The reported 73B liquid position and net-cash figure are typical of an insurer's investment portfolio rather than deployable corporate cash, so the 'fortress' framing overstates flexibility - those assets back policyholder liabilities. The Altman Z of 0.18 is a classic false signal for a financial: the model is unreliable for insurers whose balance sheets are structurally leveraged with reserves.
Verify before trusting this (5)
- Whether the 90M July 2026 P-Purchase filings are entity-level treasury actions or genuine officer/director buys - the identity of the reporting persons materially changes the signal.
- Segment-level earnings mix (PGIM asset management vs US insurance vs international/Japan) to assess durability of the 3-4B run-rate net income.
- Statutory capital ratios (RBC) and holding-company liquidity, which are the real balance-sheet strength metrics for an insurer, not GAAP cash.
- Long-term care and variable annuity reserve adequacy and hedge effectiveness - historical source of large charges at PRU.
- Dividend plus buyback payout ratio versus distributable earnings to confirm the -5.8% share shrink is sustainable.
The e2e composite pegs fair value at $72.30 and the signal-adjusted FV at $69.77, implying -42% downside from the $119.96 print. Even giving the quality lens ('Solid') a generous premium and adding back some of the 'hidden' Japan/PGIM optionality the bulls flag, it is hard to bridge more than $85-95 of deserved value on a mature life insurer whose earnings power has stepped down from the 2021 peak. The market is paying up for a business whose organic growth is low-single-digit and whose 'moat' is largely float, not free capital. That said, the anchored-PE method alone is doing all the work in the composite, and a single-method FV should not be treated as gospel. PRU is a rate-sensitive, buyback-supported name; a 5-6% buyback yield plus a ~5% dividend can defend a price above pure DCF for a while. So I would not call this 'Overvalued' with high confidence - but I see no margin of safety, and the burden of proof is on the bull case (Japan re-rating, PGIM fee acceleration) to justify $120.
Verify before trusting this (5)
- PGIM fee revenue trajectory and AUM flows in latest 10-Q - is the fee engine actually accelerating?
- Japan segment operating earnings and FX-adjusted growth - the bull 'hidden value' thesis lives here
- Normalized ROE and whether the step-down from 2021 is cyclical (rates) or structural
- Buyback pace and remaining authorization - is the -5.8% share shrink sustainable?
- Any one-time items or reserve releases inflating trailing EPS the anchored-PE relies on
PRU is carrying a 'fallen-angel' narrative with moderate intensity and only moderate durability - the market is treating it as a legacy insurance intermediary in structural decline rather than a fortress balance sheet compounder. That framing is what matters here, not the fundamentals: the story on the tape is skeptical, and the recent -13.7% move confirms sellers are in control of the near-term narrative. Cult coefficient is low, meaning there is no retail or thematic base to defend the name on down days. The macro tape is mildly risk-off (VIX 18.6, S&P off highs, 10y at 4.71%) but PRU's 0.84 beta and defensive life-insurance profile mute the direct market-wide hit. Rate sensitivity cuts both ways for a life insurer - higher yields help spread income, which is a latent tailwind, but the current narrative is not giving PRU credit for it. Net: the pressure is negative but not violent - a moderate-intensity bear story on a low-beta name in a neutral-to-soft tape, with no supportive momentum or narrative energy to lean on.
Verify before trusting this (5)
- Whether the -13.7% move is finding technical support or continuing lower
- Any analyst target cuts or upgrades that would confirm or break the fallen-angel framing
- 10y yield direction - a sharp drop would remove the latent rate tailwind and worsen sentiment
- PGIM AUM flow disclosures next earnings - fund outflows would harden the bear narrative
- Sector rotation into defensive financials which could flip the tape for PRU specifically
This lens hasn't been run for this ticker yet.
When we made this prediction on Jul 27, 2026, PRU was $119.96. We expect it to be $112.40 by Jan 2027, and we consider it great value under $90.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Jul 27, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.